SLC16A11 and neoplasm: Given the effects of conditional knockout of MCT11 in T cells, we treated tumor-bearing mice with MCT11-blocking monoclonal antibodies and found that the blockade of MCT11 could lead to clearances as a monotherapy but could also synergize with αPD1.